HGH Fragment 176-191: Complete UAE Fat Loss Peptide Guide 2026
HGH Fragment 176-191: Complete UAE Fat Loss Peptide Guide (2026)
- Fragment 176-191 is a 16-amino acid C-terminal fragment of HGH — isolates fat-burning without growth effects
- No IGF-1 increase — zero risk of insulin resistance, organ growth, or hyperglycaemia from this mechanism
- Mechanism: activates β3-adrenergic pathway → lipolysis (fat breakdown) + inhibits lipogenesis (fat storage)
- Dosage: 250–500 mcg/day subcutaneous (split AM/PM, fasted) | Nasal spray needs 10× higher dose
- Available in UAE as research compound: AED 200–400 per 5mg vial
- Often confused with AOD-9604 — they are related but chemically distinct
Among fat-loss peptides, HGH Fragment 176-191 occupies a unique position: it delivers a meaningful portion of HGH's lipolytic (fat-burning) effects while completely bypassing the growth-promoting and blood-sugar-disrupting pathways that make full HGH complicated to research.
This guide covers the science, dosage protocols, results data, and UAE-specific sourcing information for Fragment 176-191 — including the key difference between it and AOD-9604, which is one of the most commonly misunderstood distinctions in the peptide research space.
What Is HGH Fragment 176-191?
Human growth hormone (HGH) is a 191-amino-acid protein with multiple biological functions — muscle growth, fat metabolism, IGF-1 production, cellular regeneration, and more. Researchers in the 1990s identified that the fat-metabolising activity of HGH was concentrated in a specific segment of the protein's C-terminal region: amino acids 176 to 191.
Fragment 176-191 is a synthetic version of exactly that segment — 16 amino acids that replicate HGH's fat-loss mechanism without carrying the rest of the molecule's effects. The result is a compound that:
- Stimulates lipolysis (fat breakdown) in adipose tissue
- Inhibits lipogenesis (new fat formation)
- Does not increase IGF-1
- Does not affect blood glucose or insulin sensitivity
- Does not promote cell growth, muscle hypertrophy, or organ enlargement
This selective profile makes it particularly interesting for body composition research where fat reduction is the primary objective without the systemic complexity of full HGH.
Mechanism of Action: How Fragment 176-191 Burns Fat
β3-Adrenergic Pathway Activation
Fragment 176-191's primary fat-loss mechanism works through the β3-adrenergic receptor in adipose tissue. It increases β3-AR expression and enhances the receptor's coupling efficiency — making fat cells more sensitive to catecholamines (adrenaline, noradrenaline) that trigger lipolysis. The effect is dose-dependent and time-dependent, building up over a research period rather than acting as a single acute stimulus.
Hormone-Sensitive Lipase Activation
The peptide activates hormone-sensitive lipase (HSL) within adipocytes — the enzyme that breaks stored triglycerides into free fatty acids and glycerol for use as energy. This is the same mechanism through which exercise and caloric restriction promote fat loss, but initiated directly at the cellular level.
Lipogenesis Inhibition
Simultaneously, Fragment 176-191 inhibits lipogenesis — the creation of new fat from dietary carbohydrates and proteins. This dual action (breaking down existing fat while blocking new fat formation) is what makes the compound mechanistically distinct from compounds that only affect appetite or metabolic rate.
Targeted Effect on Stubborn Fat
Research in rodent models shows the lipolytic effect is particularly pronounced in visceral (abdominal) fat and other stubborn fat deposits — the same areas that respond poorly to diet and exercise alone due to lower β-adrenergic receptor density. This selectivity is one reason Fragment 176-191 attracts research interest in body composition studies.
Fragment 176-191 vs Full HGH: The Key Differences
| Characteristic | Fragment 176-191 | Full HGH |
|---|---|---|
| IGF-1 increase | None | Significant |
| Fat loss (lipolysis) | Strong and selective | Strong but non-selective |
| Muscle growth | None | Significant via IGF-1 |
| Blood glucose effect | None | Raises glucose (counters insulin) |
| Insulin resistance risk | None | Yes (dose-dependent) |
| Organ growth risk | None | Yes (long-term high dose) |
| Research cost | AED 200–400 / 5mg vial | Significantly higher |
| Dosing complexity | Low | High (IU-based, multiple injection sites) |
For research focused specifically on adipose tissue reduction and body composition — without muscle-building as a concurrent objective — Fragment 176-191 offers a simpler, lower-risk profile than full HGH. For a more detailed breakdown, see our Fragment 176-191 vs HGH comparison guide.
Fragment 176-191 Dosage Protocol
Subcutaneous Injection (Standard Protocol)
| Parameter | Recommended Range | Notes |
|---|---|---|
| Daily dose | 250–500 mcg/day | Split into 2 injections (morning + evening) |
| Injection timing | Fasted state | 30–45 min before first meal (AM) or 2h after last meal (PM) |
| Injection site | Subcutaneous | Abdomen, thigh, or upper arm |
| Cycle duration | 8–16 weeks | Most research protocols run 12 weeks |
| Reconstitution | Bacteriostatic water | Add 2mL to 5mg vial = 2.5mg/mL; 0.1mL = 250mcg |
Nasal Spray (Alternative Administration)
Fragment 176-191 nasal spray is available from some UAE suppliers. However, nasal bioavailability is significantly lower than subcutaneous — approximately 3.8–8.9% vs ~49% for subcutaneous injection. This means nasal spray requires doses approximately 5–10 times higher to achieve comparable systemic exposure. Most researchers prefer subcutaneous administration for this reason. For a full comparison, see our Fragment 176-191 dosage and delivery method guide.
Results: What Research Data Shows
It is important to set realistic expectations for Fragment 176-191 research: the majority of evidence comes from in vitro (cell culture) and in vivo rodent models. Human clinical trial data is limited — the compound was investigated in early clinical stages but did not progress to large-scale human RCTs.
Animal Model Findings
- Reduced total body fat mass, particularly visceral (abdominal) fat
- Increased fat oxidation (fat used as fuel) without changes in lean muscle mass
- No changes in food intake or appetite — the effect is purely metabolic, not anorectic
- Metabolic rate increase in treated animals vs controls
- No significant changes in blood glucose or IGF-1 in multiple rodent models
What This Means for Research
The selective fat loss without muscle loss and without appetite suppression makes Fragment 176-191 a mechanistically distinct tool from GLP-1 agonists (which reduce appetite) and from anabolic agents (which build muscle). Research applications typically pair it with caloric restriction and structured exercise to compound the lipolytic effect.
Fragment 176-191 vs AOD-9604: Are They the Same?
This is one of the most frequently confused distinctions in UAE research peptide discussions. They are related but not identical:
- Fragment 176-191: The exact C-terminal sequence from native HGH — 16 amino acids
- AOD-9604: A modified version with an additional tyrosine (Tyr) residue at the N-terminus — 17 amino acids, molecular weight ~1,978 Da vs Fragment's ~1,815 Da
The tyrosine modification gives AOD-9604 a longer half-life and potentially better bioavailability. AOD-9604 was the version that advanced to human clinical trials (though development was ultimately halted after phase 3 for obesity). For a full breakdown, see our Fragment 176-191 vs AOD-9604 comparison.
UAE Availability and Pricing (2026)
Fragment 176-191 has been available through UAE peptide suppliers for several years and has a well-established research supply chain in the region.
| Format | Typical UAE Price | Notes |
|---|---|---|
| 5mg lyophilised vial | AED 200–400 | Standard research format; reconstitution required |
| 10mg lyophilised vial | AED 350–600 | More economical per-mcg for longer research protocols |
| Nasal spray (5mg) | AED 250–450 | Lower bioavailability; requires higher dose volume |
At 250–500 mcg/day from a 5mg vial: one vial provides approximately 10–20 days of research. For a 12-week protocol at 500 mcg/day, approximately 4–5 vials are required — total cost approximately AED 800–2,000 depending on supplier.
Side Effects and Safety Profile
Fragment 176-191 has a notably clean safety profile in animal research, with adverse events matching placebo in the clinical stages it reached. Reported effects in research use include:
- Mild injection site reactions (redness, minor bruising) — common to all subcutaneous peptides
- Occasional headache (particularly at initiation)
- Transient mild joint discomfort — rare
- Temporary minor elevation in blood insulin — observed in some models, not consistently replicated
No significant effects on cardiovascular function, liver enzymes, kidney function, or thyroid have been identified in available research. The absence of IGF-1 elevation eliminates the growth-related side effect risk that makes full HGH more complex to research safely.
Frequently Asked Questions
What is HGH Fragment 176-191?
A synthetic 16-amino acid peptide from the C-terminal region of human growth hormone. It selectively stimulates fat breakdown (lipolysis) and inhibits fat storage (lipogenesis) without triggering the growth-promoting or blood-sugar effects of full HGH. It does not increase IGF-1.
Does Fragment 176-191 increase IGF-1?
No. This is the compound's key advantage over full HGH. Zero IGF-1 effect means zero risk of insulin resistance, abnormal tissue growth, or hyperglycaemia from this mechanism. The fat-loss effect is entirely separated from growth signalling.
What is the recommended dosage?
Research protocols use 250–500 mcg/day subcutaneously, split into two injections (morning and evening) in a fasted state. Reconstitute a 5mg vial with 2mL bacteriostatic water to get 2.5mg/mL; 0.1mL delivers 250 mcg.
How is Fragment 176-191 different from AOD-9604?
AOD-9604 has an additional tyrosine at the N-terminus (17 amino acids vs 16), giving it a longer half-life and potentially better bioavailability. Both target the same fat-loss pathway without IGF-1 effects. AOD-9604 advanced further in human trials. They are often sold interchangeably but are technically distinct compounds.
Is Fragment 176-191 available in the UAE?
Yes — it is available from UAE research peptide suppliers as a research compound. Pricing ranges from AED 200–400 per 5mg vial. It is not approved for human therapeutic use. Available in both lyophilised vial and nasal spray formats.
What results can be expected?
Animal studies show reduced fat mass (particularly visceral/abdominal fat), increased fat oxidation, and no lean mass changes. Human data is limited — no large-scale RCTs have been completed. Results are most pronounced with concurrent caloric restriction and exercise, typically visible after 8–12 weeks of consistent protocol.
Fragment 176-191 — UAE Research Supply
CoreSup supplies Fragment 176-191 and related peptides to UAE researchers with third-party COA testing, cold-chain delivery, and full batch documentation.
View Fat Loss Peptides →
CoreSup stocks pharmaceutical-grade bacteriostatic water (10ml, 0.9% benzyl alcohol) with same-day delivery across Dubai and all UAE emirates.
Shop Bacteriostatic Water →Shop Featured Products
Related Products
Written by Amir Arsalan
Core Sup Research Team · Peptide & Supplement Specialists, Dubai UAE
Core Sup's editorial team is composed of specialists in peptide therapy, SARMs, and sports supplementation with direct experience in the UAE market. All content is written to current research standards and reviewed before publication.
Last reviewed: March 2026 · About Core Sup
